NEW YORK (GenomeWeb News) – Skyline Diagnostics has licensed rights to TrovaGene's NPM1 technology in Europe in a microarray test for use in helping guide acute myelogenous leukemia treatment, TrovaGene said today.
Skyline will use the TrovaGene nucleophosmin protein mutation, which is found in around 35 percent of AML patients and is associated with good disease prognosis, in its AMLprofiler in vitro diagnostic assay.
A three-day test, the AMLprofiler is used to reclassify more than 50 percent of intermediate-risk AML patients into favorable or unfavorable risk groups, which helps doctors make treatment decisions. The test combines cytogenetics, mutation analysis, and expression analysis, and replaces nine separate assays, according to San Diego-based TrovaGene.
Netherlands-based Skyline Diagnostics plans to offer the lab testing services in Europe but expects to eventually expand to other markets, TrovaGene said.
Financial terms of the agreement were not released.